VPHI.F Stock Overview
A specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Valeo Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.047 |
| 52 Week High | US$0.25 |
| 52 Week Low | US$0.034 |
| Beta | 1.15 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -59.39% |
| 3 Year Change | -91.67% |
| 5 Year Change | n/a |
| Change since IPO | -94.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| VPHI.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -0.3% | -2.7% |
| 1Y | -59.4% | 7.9% | 23.4% |
Return vs Industry: VPHI.F underperformed the US Pharmaceuticals industry which returned 11.8% over the past year.
Return vs Market: VPHI.F underperformed the US Market which returned 32.6% over the past year.
Price Volatility
| VPHI.F volatility | |
|---|---|
| VPHI.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 10.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: VPHI.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine VPHI.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 70 | Al Moghaddam | www.valeopharma.com |
Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada. Its product portfolio includes Enerzair Breezhaler, a LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, a LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, for the treatment of Idiopathic Parkinson’s disease; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma. It also offers Hesperco, a flavonoid formulation used for immune support; Ethacrynate Sodium; and Amikacin, an antibiotic.
Valeo Pharma Inc. Fundamentals Summary
| VPHI.F fundamental statistics | |
|---|---|
| Market cap | US$4.63m |
| Earnings (TTM) | -US$22.77m |
| Revenue (TTM) | US$37.83m |
0.1x
P/S Ratio-0.2x
P/E RatioIs VPHI.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VPHI.F income statement (TTM) | |
|---|---|
| Revenue | CA$53.38m |
| Cost of Revenue | CA$41.36m |
| Gross Profit | CA$12.02m |
| Other Expenses | CA$44.14m |
| Earnings | -CA$32.12m |
Last Reported Earnings
Jul 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.33 |
| Gross Margin | 22.51% |
| Net Profit Margin | -60.18% |
| Debt/Equity Ratio | -110.1% |
How did VPHI.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/11/26 07:50 |
| End of Day Share Price | 2024/08/29 00:00 |
| Earnings | 2024/07/31 |
| Annual Earnings | 2023/10/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Valeo Pharma Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Neil Linsdell | iA Capital Markets |
| Chelsea Stellick | iA Capital Markets |
| Scott McAuley | Paradigm Capital, Inc. |